Catholic Health and GE HealthCare announced a 10-year strategic partnership valued at approximately $500 million, aimed at ...

A noninvasive DNA blood test can identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are most ...

As theranostics reshapes cancer care, the ability to image every therapeutic isotope on a single platform has become nuclear medicine's next frontier. Today, Spectrum Dynamics Medical, the global ...

Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leader in advanced molecular imaging technology and comprehensive PET imaging solutions, today announced three new orders for its ...

UPPI, LLC, an association of independent and university-based nuclear medicine pharmacies, today announced the appointment of Colin Spear as its new President, effective August 1, 2026. In this role, ...

GE HealthCare (Nasdaq: GEHC) today announced the introduction of MIM Anyware™, a remote access platform that provides secure, healthcare system-controlled access to imaging data through a web browser ...

First patient dosed in Phase 3 LUTEON 1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is the first Phase 3 study of a CAIX 2- ...

A body scan with Neko Health in London gave me a more refined look at my own health. I've already booked my next one.

A negative scan does not always mean recurrent prostate cancer is nowhere to be found. Sometimes, the disease may simply be ...

GE HealthCare GEHC recently announced a 10-year strategic Care Alliance with Catholic Health, valued at approximately $500 ...

On Thursday, July 16, 2026, Catholic Health and GE HealthCare pulled the curtain back on a sweeping 10-year technology ...

GE HealthCare said it will partner with Catholic Health for 10 years, in a deal worth about $500 million, to expand advanced imaging, diagnostics and AI tools across the health system's Long Island ...